A hi-tech prostate cancer drug that offers hope to men who have run out of treatment options became available in the UK today.
Enzalutamide is licensed for patients with advanced prostate cancer who are no longer responding to hormone treatments or chemotherapy.
What to expect from the new drug:
- The new pill will cost around £2,500 a month.
- It can extend the lives of patients no longer being treated by almost five months.
- Seven out of 10 of the men in the Phase III Affirm trial taking enzalutamide were still alive after one year.
- It has a relative lack of side effects.
- The drug known as Xtandi, blocks molecular signals that allow the male hormone testosterone to fuel prostate cancer.
- It targets three different steps of the signalling pathway.
More top news
When he was starting out Anthony Joshua accidentally broke his coach's wrist — and Sean Murphy still has the scars to prove it.
The verdict stemmed from ugly scenes which marred the Capital One third-round tie at Selhurst Park in September 2015.
The 25-year-old, who plays former stormtrooper Finn in the third Star Wars triolgy, takes the lead role in the new production of Woyzeck.